Product Description
VTP-300 is an immunotherapeutic agent that Vaccitech intends to administer in combination with a low-dose anti-PD-1 antibody, to counterbalance the immune suppression and T cell exhaustion in the liver caused by CHB. (Sourced from: https://www.vaccitech.co.uk/pipeline/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Arbutus Biopharma
Company Location: BURNABY A1 V5J 5J8
Company CEO: William Collier
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Arbutus Biopharma announced they will present P2 Hepatitis B, Chronic results in 1H25 for VTP-300
- Clinical Outcomes Reported - Barinthus Biotherapeutics presented P2 Hepatitis|Hepatitis, Chronic results on 2024-06-06 for VTP-300
- Clinical Outcomes Reported - Arbutus Biopharma announced they will present P2 Hepatitis B, Chronic results in 1H24 for VTP-300
Highest Development Phases
Phase 2: Hepatitis B, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACTRN12622000317796 | P2 |
Recruiting |
Hepatitis B, Chronic |
2022-08-31 |
2024-08-29 |
Patient Enrollment|Primary Completion Date|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/07/2025 |
News Article |
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 |
|
04/23/2025 |
News Article |
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 |
|
03/06/2025 |
News Article |
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 |
|
01/13/2025 |
News Article |
Arbutus Provides 2025 Corporate and Financial Update |